<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00903565</url>
  </required_header>
  <id_info>
    <org_study_id>CP-060-CR</org_study_id>
    <nct_id>NCT00903565</nct_id>
  </id_info>
  <brief_title>A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint</brief_title>
  <acronym>PARSC</acronym>
  <official_title>A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agendia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agendia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to enroll 785 eligible stage II colon cancer patients in order to&#xD;
      validate the performance of ColoPrint in estimating 3-year relapse rate.&#xD;
&#xD;
      Secondary objectives include comparing the objective risk assessment results from the&#xD;
      prognostic profile (ColoPrint) to both the risk assessment based on the ASCO criteria, as&#xD;
      well as the Investigator's independent assessment. As this is the first prospective study of&#xD;
      ColoPrint, this study will also address the logistics and quality assurance of using&#xD;
      ColoPrint in clinical practice.&#xD;
&#xD;
      Patient treatment is at the discretion of the physician, adhering to National Comprehensive&#xD;
      Cancer Network (NCCN)-approved regimens or a recognized alternative.&#xD;
&#xD;
      The enrollment period will be 6 years. It is expected that 1800 to 2400 patients will be&#xD;
      enrolled in order to obtain 785 analysable stage II samples from eligible patients.&#xD;
      Approximately 25-35 clinical sites will be involved worldwide.&#xD;
&#xD;
      The statistical analysis will be performed by Agendia and an independent research institute&#xD;
      or hospital.&#xD;
&#xD;
      Study Design Extension Study:&#xD;
&#xD;
      This will be a prospective study to measure the impact of ColoPrint on adjuvant treatment in&#xD;
      stage 2 colorectal cancer patients. After surgery the tumor sample will be shipped in RNA&#xD;
      Retain to Agendia. The online Clinical Report Form (CRF) 0 will be completed to document if&#xD;
      the patient fulfils the inclusion criteria. Baseline clinical data and the patient and&#xD;
      physician chemotherapy intention, patient's perceived recurrence risk and decisional conflict&#xD;
      without knowing the ColoPrint result will be entered in CRF 1. After completion of CRF1 the&#xD;
      ColoPrint result is released. CRF2 will be completed after the final treatment decision has&#xD;
      been made.&#xD;
&#xD;
      This CRF will capture the patient and physician chemotherapy intention, patient's perceived&#xD;
      recurrence risk and decisional conflict, impact of ColoPrint and the actual treatment the&#xD;
      patient will receive. CRF3 will be completed 12 months after enrolment and will capture the&#xD;
      patient status, patient's perceived recurrence risk and decisional conflict. CRF4 and 5 will&#xD;
      be completed 3 and 5 years after surgery and will capture the patient status. A sample size&#xD;
      of 210 stage 2 colon cancer patients is required to detect a 10% overall treatment change (5%&#xD;
      significance and 90% power).&#xD;
&#xD;
      Reporting of the Results:&#xD;
&#xD;
      Blinded Study; The ColoPrint results will not be reported to the physician and/or patient at&#xD;
      the time of enrolment. All samples will be stored in a freezer until 550-575 eligible stage&#xD;
      II patients have been enrolled. Samples will then be analyzed in one batch in a blinded&#xD;
      fashion from the clinical results.&#xD;
&#xD;
      Extension Study; The ColoPrint results will be reported to the physician and patient after&#xD;
      CRF1 has been completed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective • To validate the performance of ColoPrint in estimating the 3-year relapse&#xD;
      rate in patients with stage II colorectal cancer.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
      • To assess the feasibility of using the ColoPrint test in the clinical setting.&#xD;
&#xD;
        -  To compare the risk assessment in stage II patients using the ColoPrint profile vs a&#xD;
           clinical risk assessment based on 1) Investigator's assessment of risk and 2) ASCO&#xD;
           high-risk recommendations (T4 lesions, perforation / obstruction, inadequate node&#xD;
           sampling (less than 12 nodes) or poorly differentiated histology).&#xD;
&#xD;
        -  To establish the proportion of low-risk and high-risk ColoPrint profiles in stage II&#xD;
           colorectal cancer patients in various countries.&#xD;
&#xD;
        -  To investigate therapy as a potential confounding factor for ColoPrint results.&#xD;
&#xD;
        -  To assess the performance of ColoPrint in estimating the 3-year relapse rate in patients&#xD;
           with stage III colorectal cancer.&#xD;
&#xD;
        -  To compare the performance of ColoPrint vs the clinical risk assessment in estimating&#xD;
           the 5-year relapse rate.&#xD;
&#xD;
        -  Assess the impact of ColoPrint on adjuvant chemotherapy treatment decisions in stage 2&#xD;
           colorectal cancer patients&#xD;
&#xD;
        -  Compare the ColoPrint results from fresh RNARetain colorectal tumor specimens to the&#xD;
           matched formalin-fixed paraffin-embedded tissue (FFPE) colon tumor specimens for&#xD;
           concordance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To validate the performance of ColoPrint in estimating the 3-year relapse rate in patients with stage II colorectal cancer.</measure>
    <time_frame>The enrolment period will be 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• To assess the feasibility of using the ColoPrint test in the clinical setting.</measure>
    <time_frame>The enrolment period will be 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• To compare the risk assessment in stage II patients using the ColoPrint profile vs a clinical risk assessment</measure>
    <time_frame>The enrolment period will be 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• To establish the proportion of low-risk and high-risk ColoPrint profiles in stage II colorectal cancer patients in various countries.</measure>
    <time_frame>The enrolment period will be 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• To investigate therapy as a potential confounding factor for ColoPrint results.</measure>
    <time_frame>The enrolment period will be 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• To assess the performance of ColoPrint in estimating the 3-year relapse rate in patients with stage III colorectal cancer.</measure>
    <time_frame>The enrolment period will be 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• To compare the performance of ColoPrint vs the clinical risk assessment in estimating the 5-year relapse rate.</measure>
    <time_frame>The enrolment period will be 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Assess the impact of ColoPrint on adjuvant chemotherapy treatment decisions in stage 2 colorectal cancer patients</measure>
    <time_frame>The enrolment period will be 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Compare the ColoPrint results from fresh RNARetain colorectal tumor specimens to the matched formalin-fixed paraffin-embedded tissue (FFPE) colon tumor specimens for concordance.</measure>
    <time_frame>The enrolment period will be 6 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Colon Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients recruited from participating hospitals worldwide&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  adenocarcinoma of the colon or rectum&#xD;
&#xD;
          -  stage II-III, planned to be treated with radical surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior malignancy with the exception of basal cell carcinoma or cervical dysplasia&#xD;
&#xD;
          -  any neo-adjuvant therapy&#xD;
&#xD;
          -  synchronous tumors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramon Salazar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Català D´Oncologia, L'Hospitalet Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John L Marshall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief, Division of Hematology/Oncology, Georgetown University Hospital Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glendale Memorial Hospital</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Orange County Surgical Medical Group</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Roseville Medical Center /Research</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Colon and Rectal Surgery</name>
      <address>
        <city>Riverdale</city>
        <state>Georgia</state>
        <zip>30274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine, Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan Research Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hong Kong/ Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle-Paul Lamarque</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsuda Hospital</name>
      <address>
        <city>Hamamatsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westfriesgasthuis</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d' Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IDIBELL Institut Catala d'Oncologia (ICO)</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immunology Akademiska sjukhuset/ University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>China</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.agendia.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 15, 2009</study_first_submitted>
  <study_first_submitted_qc>May 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2009</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>genomic profiling</keyword>
  <keyword>gene expression</keyword>
  <keyword>ColoPrint</keyword>
  <keyword>adenocarcinoma colon</keyword>
  <keyword>recurrence risk assessment</keyword>
  <keyword>prospective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

